Design
neurological deficit, cancer, CNLBP
CANCER, CARDIAC DISEASE, METASTATIC CANCER
A longitudinal, single-blind, randomized controlled trial study was conducted between August 2017 and November 2018. This study was registered on clinicaltrials.gov (NCT03097497) on 31/03/2017 and followed the Consolidated Standards of Reporting Trials statement (CONSORT) recommendations to develop the structure and guide the performance of the study [The inclusion criteria were adults (18 to 65 years old) diagnosed with CNLBP, with a minimum of 3 months of follow-up.The exclusion criteria were signs of neurological deficit, history of spinal surgery or cardiac disease, cancer or metastatic cancer treatment in the previous five years, and pregnancy or plan to become pregnant or less than three months postpartum.